Autologous stem cell and non-stem cell-based therapies refer to treatments that use a patient’s own cells to repair, replace, or regenerate damaged tissues and organs. Autologous stem cell therapies involve extracting stem cells from the patient, expanding or modifying them, and then reinfusing them to promote healing and regeneration. Non-stem cell-based therapies use other types of cells, such as immune cells or tissue-specific cells, to achieve similar therapeutic goals. These personalized approaches aim to minimize the risk of immune rejection and enhance the efficacy of treatments for various conditions, including cancer, autoimmune diseases, and degenerative disorders.
Sizing and Forecast
The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $9.96 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increased prevalence of cancer and diabetes, increased numbers of geriatric individuals, growing healthcare awareness, rise in research and development activities, increased numbers of clinical trials, Increased regulatory approval.
The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising prevalence of targeted diseases, an increasing geriatric population, rising prevalence of neurodegenerative diseases, growing number of cancer cases, increasing demand for skin transplantation, increasing awareness about regenerative medicine, collaborations and partnerships among key players, improving reimbursement for approved therapies. Major trends in the forecast period include the integration of artificial intelligence and machine learning, development of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, adoption of novel biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, integration of gene editing technologies.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/autologous-stem-cell-and-non-stem-cell-based-therapies-global-market-report
Segmentation & Regional Insights
The autologous stem cell and non-stem cell based therapies market covered in this report is segmented –
1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types
2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications
3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users
North America was the largest region in the autologous stem cell and non-stem cell based therapiesmarket in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15729&type=smp
Major Driver Impacting Market Growth
The demand for personalized therapies is expected to propel the growth of the autologous stem cell and non-stem cell-based therapies market going forward. Personalized therapies are medical treatments designed to maximize benefits and minimize adverse effects based on a patient’s unique genetics, lifestyle, and preferences. Personalized therapies are on the rise owing to several factors, such as advances in genetics and technology that allow for more precise and effective treatments with fewer side effects, increased patient demand for tailored care, and the potential for healthcare cost savings. Personalized therapies improve the use of autologous stem cell and non-stem cell-based treatments by customizing them to a person’s unique genetic and health characteristics, leading to better results and fewer complications. For instance, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the demand for personalized therapies drives the autologous stem cell and non-stem cell-based therapies market.
Key Industry Players
Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group
The autologous stem cell and non-stem cell based therapies market report table of contents includes:
1. Executive Summary
2. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Characteristics
3. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Trends And Strategies
4. Autologous Stem Cell And Non-Stem Cell Based Therapies Market – Macro Economic Scenario
5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Size and Growth
….
32. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Benchmarking
33. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market
35. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
